Corbus Free Cash Flow vs Operating Income Analysis
CRBP Stock | USD 39.24 2.71 7.42% |
Corbus Pharmaceuticals financial indicator trend analysis is way more than just evaluating Corbus Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corbus Pharmaceuticals is a good investment. Please check the relationship between Corbus Pharmaceuticals Free Cash Flow and its Operating Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Free Cash Flow vs Operating Income
Free Cash Flow vs Operating Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corbus Pharmaceuticals Free Cash Flow account and Operating Income. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Corbus Pharmaceuticals' Free Cash Flow and Operating Income is 0.98. Overlapping area represents the amount of variation of Free Cash Flow that can explain the historical movement of Operating Income in the same time period over historical financial statements of Corbus Pharmaceuticals Holding, assuming nothing else is changed. The correlation between historical values of Corbus Pharmaceuticals' Free Cash Flow and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Free Cash Flow of Corbus Pharmaceuticals Holding are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Free Cash Flow i.e., Corbus Pharmaceuticals' Free Cash Flow and Operating Income go up and down completely randomly.
Correlation Coefficient | 0.98 |
Relationship Direction | Positive |
Relationship Strength | Very Strong |
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Operating Income
Operating Income is the amount of profit realized from Corbus Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Corbus Pharmaceuticals Holding is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.Most indicators from Corbus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corbus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. At this time, Corbus Pharmaceuticals' Selling General Administrative is relatively stable compared to the past year. As of 04/19/2024, Sales General And Administrative To Revenue is likely to grow to 21.89, while Issuance Of Capital Stock is likely to drop slightly above 231.9 K.
Corbus Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Corbus Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Corbus Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Common Stock Shares Outstanding | 2.1M | 2.6M | 4.1M | 4.2M | 4.3M | 2.9M | |
Total Assets | 49.1M | 102.3M | 107.7M | 66.3M | 28.3M | 50.5M | |
Short Long Term Debt Total | 9.4M | 26.8M | 26.6M | 25.1M | 20.9M | 11.1M | |
Other Current Liab | 22.4M | 797K | 133.7K | 6.0M | 11.1M | 5.9M | |
Total Current Liabilities | 34.9M | 31.9M | 17.0M | 12.6M | 31.9M | 16.9M | |
Total Stockholder Equity | 6.2M | 45.3M | 69.1M | 33.0M | (6.9M) | (6.6M) | |
Net Debt | (22.3M) | (58.6M) | 1.6M | 8.1M | 7.0M | 7.3M | |
Retained Earnings | (192.8M) | (304.1M) | (349.7M) | (392.1M) | (436.7M) | (414.8M) | |
Accounts Payable | 11.1M | 7.4M | 1.8M | 2.2M | 3.2M | 4.0M | |
Cash | 31.7M | 85.4M | 25.0M | 17.0M | 13.9M | 13.2M | |
Cash And Short Term Investments | 31.7M | 85.4M | 97.6M | 59.2M | 21.1M | 20.0M | |
Common Stock Total Equity | 5.6K | 5.7K | 6.5K | 9.9K | 11.4K | 11.9K | |
Liabilities And Stockholders Equity | 49.1M | 102.3M | 107.7M | 66.3M | 28.3M | 50.5M | |
Non Current Liabilities Total | 8.1M | 25.1M | 21.6M | 20.7M | 3.3M | 3.1M | |
Other Current Assets | 6.4M | 3.7M | 2.4M | 791.6K | 2.4M | 2.3M | |
Other Stockholder Equity | 199.0M | 349.4M | 418.9M | 425.2M | 429.8M | 216.4M | |
Total Liab | 43.0M | 57.0M | 38.6M | 33.3M | 35.2M | 25.1M | |
Total Current Assets | 38.2M | 92.1M | 100.2M | 60.2M | 23.5M | 46.1M | |
Short Term Debt | 1.3M | 1.7M | 5.0M | 4.4M | 17.6M | 18.5M | |
Common Stock | 6.5K | 9.9K | 12.5K | 417.0 | 442.0 | 419.9 | |
Net Tangible Assets | 6.2M | 45.3M | 69.1M | 33.0M | 37.9M | 32.1M | |
Property Plant And Equipment Net | 10.9M | 9.3M | 7.0M | 5.5M | 4.0M | 4.6M | |
Non Current Assets Total | 11.0M | 10.2M | 7.5M | 6.1M | 4.7M | 4.9M | |
Non Currrent Assets Other | 85.0K | 234.0K | 46.4K | 155.3K | 212.8K | 223.4K | |
Retained Earnings Total Equity | (65.7M) | (121.4M) | (192.8M) | (304.1M) | (273.7M) | (260.0M) | |
Capital Surpluse | 123.5M | 148.9M | 199.0M | 349.4M | 401.8M | 421.9M | |
Property Plant And Equipment Gross | 10.9M | 9.3M | 7.0M | 5.5M | 7.6M | 5.0M | |
Short Long Term Debt | 752.7K | 710.2K | 3.9M | 3.1M | 16.2M | 17.0M | |
Accumulated Other Comprehensive Income | (666.6K) | (1.4M) | (62.4K) | (126.1K) | (1.6K) | (1.6K) | |
Property Plant Equipment | 5.1M | 9.3M | 7.0M | 5.5M | 6.3M | 3.9M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Corbus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Corbus Pharmaceuticals' short interest history, or implied volatility extrapolated from Corbus Pharmaceuticals options trading.
Pair Trading with Corbus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against Corbus Stock
0.54 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.
The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Corbus Pharmaceuticals information on this page should be used as a complementary analysis to other Corbus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Complementary Tools for Corbus Stock analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Transaction History View history of all your transactions and understand their impact on performance | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Corbus Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.31) | Quarterly Revenue Growth (1.00) | Return On Assets (0.60) | Return On Equity (3.42) |
The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.